| Literature DB >> 35889130 |
Danielle Saraiva Tuma Dos Reis1, Mioni Thieli Figueiredo Magalhães de Brito2, Ricardo José de Paula Souza Guimarães3, Juarez Antônio Simões Quaresma4.
Abstract
The Brazilian Amazon has a specific epidemiological profile for cryptococcosis, considering its social and economic inequality, health reality, and low access to health services. Furthermore, Brazil and Colombia have the highest cryptococcosis incidence rates in Latin America. In this study, we identified the areas of risk for cryptococcosis in the state of Pará in the Brazilian Amazon. This was an ecological study of patients admitted to a referral hospital from 2008 to 2018, aged 13 years or older, and of both sexes. The spatial distribution was determined using ArcGis 10.3.1 software. Cryptococcosis was confirmed in 272 cases. The incidence rate was 3.41 cases/100,000 inhabitants. Spatial distribution was concentrated in the Metropolitana de Belém, Nordeste Paraense, and Marajó mesoregions. The sociodemographic profile consisted of 62% men, aged between 24 and 34 years (36%), without completed secondary education (64.7%), and with occupations varying between agricultural activities (13.8%) and household activities (22%). The mean hospitalization time was 39 days; the prevalent clinical form was neurological (89.7%). The mortality rate among patients with cryptococcosis was up to 40%. Knowledge of the real magnitude of the disease in the Brazilian Amazon makes it possible to identify areas with the greatest risks and to propose control and epidemiological surveillance programs.Entities:
Keywords: cryptococcosis; epidemiological profiles; spatial analysis; time-series studies
Year: 2022 PMID: 35889130 PMCID: PMC9324227 DOI: 10.3390/microorganisms10071411
Source DB: PubMed Journal: Microorganisms ISSN: 2076-2607
Sociodemographic profile of patients with cryptococcosis, 2008–2018, JBBUH, Pará, Brazil.
| Variables | N | % |
|---|---|---|
| Sex | ||
| Female | 103 | 38.0 |
| Male | 169 | 62.0 |
| Age Range | ||
| 13–23 | 53 | 19.5 |
| 24–34 | 98 | 36.0 |
| 35–45 | 77 | 28.3 |
| 46–56 | 33 | 12.1 |
| 57–67 | 11 | 4.0 |
| Schooling | ||
| HS incomplete | 176 | 64.7 |
| HS complete | 64 | 23.5 |
| UE incomplete | 9 | 3.3 |
| UE complete | 8 | 2.9 |
| No registry | 15 | 5.5 |
| Professional occupations | ||
| Household activities | 54 | 22.0 |
| Agricultural activities | 34 | 13.8 |
| Student | 32 | 13.0 |
| Self-employed | 15 | 6.1 |
| Merchant | 13 | 5.3 |
| Bricklayer | 11 | 4.5 |
| Teacher | 11 | 4.5 |
| Unemployed | 9 | 3.7 |
| Clerk | 8 | 3.3 |
| Driver | 8 | 3.3 |
| Servant | 7 | 2.8 |
| Hairdresser | 6 | 2.4 |
| Others | 28 | 15.4 |
Source: Authors’ research (2019). HS-high school, UE-university education.
Clinical and laboratory profile of patients with cryptococcosis, 2008–2018, JBBUH, Pará, Brazil.
| Variables | N (272) | % |
|---|---|---|
| Hospitalization time | ||
| 1–15 | 72 | 26.5 |
| 16–30 | 53 | 19.5 |
| 31–60 | 88 | 32.3 |
| >60 days | 59 | 21.7 |
| Time of disease onset | ||
| Acute < 7 days | 80 | 31 |
| Subacute 7–29 days | 120 | 46 |
| Chronic > 30 days | 59 | 23 |
| Signs and Symptoms | ||
| Headache | 245 | 90.1 |
| Fever | 207 | 76.1 |
| Vomiting | 194 | 71.3 |
| Stiffness of nape | 89 | 32.7 |
| Other symptoms | 70 | 25.7 |
| Laboratory tests | ||
| Direct detection of fungus in CSF | 267 | 98.2% |
| Cultures | 193 | 70.9% |
| Tomography | 29 | 10.7% |
| Biopsy | 4 | 1.5% |
| CSF analysis | ||
| Cellularity mm3 | ||
| 0–10 cells | 70 | 27.8% |
| 11–500 cells | 163 | 64.7% |
| 501–1000 cells | 11 | 4.4% |
| >1000 cells | 8 | 3.1% |
| Predominant cell | ||
| Mononuclear cells | 225 | 88.9% |
| Polymorphonuclear cells | 28 | 11.1% |
| Glycorrhachia | ||
| <40 | 141 | 55.1% |
| ≥40 | 115 | 44.9% |
| Proteinorrachia | ||
| <40 | 51 | 21.4% |
| 40–100 | 116 | 48.7% |
| 101–200 | 47 | 19.7% |
| >200 | 24 | 10.2% |
Source: Authors’ research (2019).
Antifungal treatment applied to patients with cryptococcosis according to clinical evolution, 2008–2018, JBBUH, Pará, Brazil.
| Antifungal Treatment | Clinically | % | Death | % | Total | |
|---|---|---|---|---|---|---|
| AmB/Fluconazole | 115 | 78.7% | 31 | 21.3% | 146 | <0.0001 a |
| Fluconazole | 5 | 83.3% | 1 | 16.7% | 6 | |
| AmB | 25 | 39.7% | 38 | 60.3% | 63 |
Source: Authors’ research (2019). Amphotericin B deoxycholate (AmB). a Test G.
Figure 1Distribution of the number of new cases of cryptococcosis per year and the incidence rate by state population per 100,000 inhabitants, 2008–2018, JBBUH, Pará, Brazil.
Clinical evolution of patients with cryptococcosis according to the present immunological condition, 2008–2018, JBBUH, Pará, Brazil.
| Clinical Evolution | Hiv− | % | Hiv+ | % | |
|---|---|---|---|---|---|
| Clinically improved | 73 | 71.6% | 90 | 52.9% | 0.0036 b |
| Mortality | 29 | 28.4% | 80 | 47.1% |
Source: Authors’ research 206 (2019). b Chi-square test.
Figure 2Spatial distribution of the incidence rate of cryptococcosis according to the population of the mesoregions of the Pará per 100,000/inhabitants. (IBGE). 2008–2018, JBBUH, Pará, Brazil.